Biogen Inc. (BIIB)

NMS – Real vaqt narxi. Valyuta: USD

199.36

+1.41 (0.71%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd.

07.05.2026

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Pointe Homes Inc. (NYSE: TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.

07.05.2026

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2026, and announced new 4-year longitudinal d.

30.04.2026

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings

Biogen (NASDAQ:BIIB) reported upbeat earnings for the first quarter on Wednesday.

29.04.2026

Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript

29.04.2026

Big Boosts to Econ Growth from AI Investment, Inventories & More

For once, there is something even bigger than the Strait of Hormuz affecting investors' attitudes this morning.

29.04.2026

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Videolar

13.01.2026

Positive

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Press-relizlar

08.05.2026

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd.

07.05.2026

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

07.05.2026

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

20.04.2026

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each,.

Biogen Inc. (BIIB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Biogen Inc. (BIIB)

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings

Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript

Big Boosts to Econ Growth from AI Investment, Inventories & More

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Videolar

Press-relizlar

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings

Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript

Big Boosts to Econ Growth from AI Investment, Inventories & More

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Videolar

Press-relizlar

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Search stocks

Biogen Inc. (BIIB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Biogen Inc. (BIIB)

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings

Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript

Big Boosts to Econ Growth from AI Investment, Inventories & More

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Videolar

Press-relizlar

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings

Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript

Big Boosts to Econ Growth from AI Investment, Inventories & More

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Videolar

Press-relizlar

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS